The efficacy of apatinib plus topotecan as laterline therapy for advanced small cell lung cancer

被引：0
|
作者：
Qin, H. [1 ]
Wang, F. [1 ]
Wang, S. S. [1 ]
Zeng, Z. [1 ]
Gao, H. [1 ]
机构：
[1] PLA AMMS China, Hosp 307, Dept Pulm Neoplasm Internal Med, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1804P
引用
收藏
页码：S1043 / S1043
页数：1
相关论文
共 50 条
  • [31] Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy
    PN Mainwaring
    MC Nicolson
    T Hickish
    R Penson
    S Joel
    M Slevin
    IE Smith
    British Journal of Cancer, 1997, 76 : 1636 - 1639
  • [32] Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy
    Mainwaring, PN
    Nicolson, MC
    Hickish, T
    Penson, R
    Joel, S
    Slevin, M
    Smith, IE
    BRITISH JOURNAL OF CANCER, 1997, 76 (12) : 1636 - 1639
  • [33] Topotecan active as first-line combination therapy for advanced non-small-cell lung cancer
    不详
    ONCOLOGY-NEW YORK, 2001, 15 (02): : 186 - +
  • [34] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S873 - S873
  • [35] Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
    Gao, Guanghui
    Ni, Jian
    Wang, Yina
    Ren, Shengxiang
    Liu, Zhihua
    Chen, Gongyan
    Gu, Kangsheng
    Zang, Aimin
    Zhao, Jun
    Guo, Renhua
    He, Jianxing
    Lin, Xiaoyan
    Pan, Yueyin
    Ma, Zhiyong
    Wang, Zhehai
    Fan, Min
    Liu, Yunpeng
    Cang, Shundong
    Yang, Xinfeng
    Li, Weixia
    Wang, Quanren
    Zhou, Caicun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (06) : 964 - +
  • [36] CLINICAL EFFICACY OF VINORELBINE PLUS CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER
    童茂荣
    夏锡荣
    曹鄂洪
    施毅
    赵蓓蕾
    Chinese Journal of Cancer Research, 1996, (03) : 74 - 76
  • [37] Clinical response to apatinib monotherapy in advanced non-small cell lung cancer
    Xu, Jianping
    Liu, Xiaoyan
    Yang, Sheng
    Zhang, Xiangru
    Shi, Yuankai
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (03) : 264 - 269
  • [38] Apatinib plus icotinib in treating advanced non-small-cell lung cancer after icotinib treatment failure.
    Xu, Jianping
    Liu, Xiaoyan
    Yang, Sheng
    Zhang, Xiangru
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Apatinib plus icotinib in treating advanced non small cell lung cancer after icotinib treatment failure: a retrospective study
    Xu, Jianping
    Liu, Xiaoyan
    Yang, Sheng
    Zhang, Xiangru
    Shi, Yuankai
    ONCOTARGETS AND THERAPY, 2017, 10 : 4989 - 4995
  • [40] Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy
    Liu, Zui
    Ou, Wei
    Li, Ning
    Wang, Si-Yu
    THORACIC CANCER, 2018, 9 (10) : 1285 - 1290
12345